<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848445</url>
  </required_header>
  <id_info>
    <org_study_id>CAFÃ‰</org_study_id>
    <nct_id>NCT00848445</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -</brief_title>
  <acronym>CAFE</acronym>
  <official_title>the Use of Atrial Fibrillation Pacing Therapies in Patients With no Previous History of Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether atrial fibrillation (AF) therapies in Guidant Pulsar Max II or Insignia&#xD;
      Plus DR have an effect on the occurance of AF in patients with no prior history of AF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-centre, randomized, cross-over, prospective study will evaluate the occurrence of&#xD;
      AF with AF pacing therapies programmed on (APP and VRR) and with AF therapies programmed off&#xD;
      (APP and VRR) in patients with no known prior history of AF (all patients have a pacing&#xD;
      indication). The occurrence of AF as well as time to first event and AF burden (frequecy and&#xD;
      duration).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2002</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the occurrence of AF (&gt;350 bpm) during a period when AF pacing therapies are programmed on (APP and VRR) and during when AF therapies are programmed off.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare AF burden between patients with AF therapies programmed on (APP and VRR) and patients with AF pacing therapies turned off (APP and VRR). Burden is defined as the product of the number of AF events and duration of events. To compare the time to</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>APP and VRR on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APP and VRR turned on at 2 week visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APP and VRR off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>APP and VRR turned off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guidant Pulsar Max II or Insignia Plus DR</intervention_name>
    <description>market approved pacemaker. programmed per protocol</description>
    <arm_group_label>APP and VRR off</arm_group_label>
    <arm_group_label>APP and VRR on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial pacing preference turned on or off</intervention_name>
    <description>programing changes in the device</description>
    <arm_group_label>APP and VRR off</arm_group_label>
    <arm_group_label>APP and VRR on</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No prior history of AF or atrial flutter, primary indication of SSS or AV block for&#xD;
             dual chamber pacemaker, confidentiality agreement signed and dated before implant,&#xD;
             available for follow-up at the study centre where they were enrolled at the protocol&#xD;
             defined intervals, willing and capable of participating in all testing associated with&#xD;
             the study, on stable regime of arrhythmia management drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of AF or atrial flutter, clinically significant ventricular&#xD;
             arrhythmias, &lt; 18 yrs old, life expectancy &lt; 1 year or expectation of heart&#xD;
             transplantation during the study period, likely to or have received a mechanical&#xD;
             tricuspid valve during the study, enrolled in other cardiovascular studies, women who&#xD;
             are pregnant, inability or refusal to sign Patient Confidentiality Agreement,&#xD;
             inability or refusal to complete the follow-up schedule at the study centre in which&#xD;
             they were enrolled, exhibit arrhythmias due to reversible cause eg, digitalis&#xD;
             toxicity, hypoxia, transient electrolyte imbalance, acute myocardial infarction or&#xD;
             electrocution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Sterns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Victoria Cardiac Arrythmia trials</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <name_title>Dr Lawrence Sterns (PI)</name_title>
    <organization>Victoria Cardiac Arrythmia Trials</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

